

Express Mail Label No.: EV05296255US
Date of Deposit: January 18, 2002

Attorney Docket No. 15966-697 (Cura-197)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Vermet, et al.

SERIAL NO.: 09/800,198

FILING DATE: March 5, 2001


FOR: Novel Proteins and Nucleic Acids Encoding Same

EXAMINER: Not Yet Assigned

ART UNIT: 1646

Box IDS

Assistant Commissioner for Patents
Washington, D.C. 20231



#10
DB
1/30/02
RECEIVED
JAN 28 2002
TECH CENTER 160012900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references. This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the Partial International Search Report in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 15966-697 (Cura-197).

Respectfully submitted,



Ivor R. Elriff, (Reg. No. 39,529)
Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS

GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: January 18, 2002

TRA 1619057v1